Innoviva (INVA) Expected to Announce Earnings on Wednesday

Innoviva (NASDAQ:INVA) is projected to announce its Q2 2025 earnings results before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $87.10 million for the quarter.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.25 EPS for the quarter. Innoviva had a negative net margin of 16.15% and a positive return on equity of 15.77%. The firm had revenue of $88.63 million for the quarter. On average, analysts expect Innoviva to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Innoviva Price Performance

Shares of NASDAQ INVA opened at $18.72 on Monday. The firm has a market cap of $1.18 billion, a P/E ratio of -18.53 and a beta of 0.37. Innoviva has a twelve month low of $16.67 and a twelve month high of $22.00. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 0.40. The company has a 50 day moving average of $19.99 and a 200 day moving average of $18.73.

Institutional Trading of Innoviva

Hedge funds have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Innoviva by 21.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 171,116 shares of the biotechnology company’s stock worth $3,102,000 after acquiring an additional 30,792 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Innoviva by 17.8% in the 1st quarter. AQR Capital Management LLC now owns 167,456 shares of the biotechnology company’s stock valued at $3,036,000 after purchasing an additional 25,317 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Innoviva by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,882 shares of the biotechnology company’s stock worth $596,000 after purchasing an additional 1,392 shares during the period. Royal Bank of Canada boosted its holdings in shares of Innoviva by 81.1% in the 1st quarter. Royal Bank of Canada now owns 21,530 shares of the biotechnology company’s stock worth $389,000 after purchasing an additional 9,639 shares during the period. Finally, NewEdge Advisors LLC bought a new position in shares of Innoviva during the 1st quarter valued at approximately $243,000. 99.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on INVA. Wall Street Zen upgraded Innoviva from a “hold” rating to a “buy” rating in a research note on Wednesday, April 30th. HC Wainwright assumed coverage on Innoviva in a research report on Monday, July 14th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on Innoviva in a research note on Friday, July 11th. They set an “overweight” rating and a $26.00 price target for the company.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.